1. Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes. (April 2014) Authors: Baker, D J; Atkinson, A M; Wilkinson, G P; Coope, G J; Charles, A D; Leighton, B Journal: British journal of pharmacology Issue: Volume 171:Number 7(2014:Apr.) Page Start: 1629 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes. (April 2014) Authors: Baker, D J; Wilkinson, G P; Atkinson, A M; Jones, H B; Coghlan, M; Charles, A D; Leighton, B Journal: British journal of pharmacology Issue: Volume 171:Number 7(2014:Apr.) Page Start: 1642 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Continuous inhibition of 11β‐hydroxysteroid dehydrogenase type I in adipose tissue leads to tachyphylaxis in humans and rats but not in mice. (8th October 2015) Authors: Morentin Gutierrez, P; Gyte, A; deSchoolmeester, J; Ceuppens, P; Swales, J; Stacey, C; Eriksson, J W; Sjöstrand, M; Nilsson, C; Leighton, B Journal: British journal of pharmacology Issue: Volume 172:Number 20(2015:Oct.) Page Start: 4806 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗